Pixium Vision: Advancements For Iris Ii, Prima In 2017
Edison | Mar 31, 2017 01:51AM ET
Pixium Vision (PA:PIX) is developing two different retinal implants that provide vision by electrically stimulating the retina. Commercialisation efforts for Iris II are starting in Europe. Prima intends to target a larger population, and human trials could start in H117. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €131.4m, up from €125.5m, previously.
With CE Mark, Iris II gearing for initial EU sales
The Iris II epi-retinal implant received CE Mark clearance in 2016, and is designed to partially restore vision in profoundly blind retinitis pigmentosa (RP) patients. Pixium is building up a sales channel across Europe and the Middle East, and finished recruitment for a 10-patient study. It is seeking conditional reimbursement in Germany and France, and in February 2017 received a positive decision in Germany where it was granted NUB Status-1 (full approval). This allows selected hospitals to negotiate with insurance providers to obtain maximum Iris II coverage.
To read the entire report Please click on the pdf File Below
Pixium Vision - Key Advancements For Iris Ii And Prima In 2017
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.